12/01/1997
https://www.congress.gov...
These regulatory requirements are an important safeguard to ensure that drugs with potentially dangerous characteristics...
which of these factors is most pressing and what recommendations on substantive solutions can we in Congress work on to ...
This cap to me is simply unconscionable.
We should also use this as an opportunity to review the procedures at the United States Patent and Trademark Office.